Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
Active, not recruiting · Phase 3 · NCT03701282
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $36.7M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 720
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Biospecimen Collection (procedure), Bone Marrow Biopsy (procedure), Computed Tomography (procedure), Ibrutinib (drug), Obinutuzumab (biological), Quality-of-Life Assessment (other), Venetoclax (drug)
- Dates
- Started 2019-02-12; completion 2028-05-07
- Results posted
- Not yet
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving ibrutinib, obinutuzumab, and venetocl…
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $36.7M in research payments for this study in 2025 (13 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- National Institute of Health $36.7M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.